InPha Pharmaceuticals (07630) has officially been included in the Hong Kong Stock Connect, opening up a channel for mainland investors to participate.
According to the relevant provisions of the Implementation Measures for Shanghai-Hong Kong Stock Connect of the Shanghai Stock Exchange, Inphy Pharmaceutical (07630) has officially been included in the list of eligible securities for the Hong Kong Stock Connect. This adjustment will take effect from September 7 (Monday).
On September 4th, the Shanghai Stock Exchange issued a notice stating that according to the relevant provisions of the "Implementation Measures for Shanghai-Hong Kong Stock Connect," Impax Laboratories (07630) has officially been added to the list of eligible securities for the Hong Kong Stock Connect. This adjustment will take effect on September 7th (Monday). This means that mainland investors can now directly buy and sell Impax Laboratories through the Shanghai and Shenzhen-Hong Kong Stock Connect, officially unlocking southbound funds.
Related Articles
TRAD CHI MED (00570): The innovation drug for category 1 traditional Chinese medicine, Xingpi Jieyu Tablets, has been approved for market launch.
KN HOSPITAL (02120) will distribute an interim dividend of HKD 2.081 per 10 shares on October 5.
AIRDOC-B (02251) repurchased 10,300 shares on September 4 at a cost of approximately HKD 86,000.
TRAD CHI MED (00570): The innovation drug for category 1 traditional Chinese medicine, Xingpi Jieyu Tablets, has been approved for market launch.
KN HOSPITAL (02120) will distribute an interim dividend of HKD 2.081 per 10 shares on October 5.
AIRDOC-B (02251) repurchased 10,300 shares on September 4 at a cost of approximately HKD 86,000.
RECOMMEND
